Login to Your Account



Other News To Note


Thursday, July 19, 2012
• Hemispherx Biopharma Inc., of Philadelphia, said it submitted a new drug application for Ampligen for the treatment of chronic fatigue syndrome to regulatory authorities in Argentina, under its orphan drug regulations. GP Pharm SA, of Gava, Spain, is Hemispherx's partner in Argentina and is responsible for commercialization of Ampligen and Alferon N Injection, which gained regulatory approval in Argentina earlier this year for the treatment of genital warts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription